These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38692087)

  • 1. Peak plasma anti-Xa direct oral anticoagulant levels after gastrointestinal surgeries: A retrospective cohort.
    Huroy M; Selby R; Sutradhar S; Galanaud JP; Abdulrehman J
    Thromb Res; 2024 Jun; 238():85-87. PubMed ID: 38692087
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urgent Need to Measure Effects of Direct Oral Anticoagulants.
    Weitz JI; Eikelboom JW
    Circulation; 2016 Jul; 134(3):186-8. PubMed ID: 27436877
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
    Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
    JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa inhibitors in the prevention of cancer-related venous thromboembolism: lessons learned by clinical trials.
    Lavalle C; V Mariani M; Fedele F
    Future Oncol; 2020 Nov; 16(32):2591-2594. PubMed ID: 32805155
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery.
    Hakeam HA; Alkhani M; Alyahya Z; Alawaji Z; Ofori S
    J Cardiovasc Pharmacol; 2021 Dec; 78(6):867-874. PubMed ID: 34882113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
    Robertson L; Kesteven P; McCaslin JE
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
    Marcy TR; Truong T; Rai A
    Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis.
    Tu ZH; Perez AD; Diaz TE; Loop MS; Clarke M
    Tex Heart Inst J; 2024 May; 51(1):. PubMed ID: 38748549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.
    Celik F; Huitema AD; Hooijberg JH; van de Laar AW; Brandjes DP; Gerdes VE
    Obes Surg; 2015 Apr; 25(4):628-34. PubMed ID: 25223871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Relationship between the Initial Anti-factor Xa Measurement and the Duration of Direct Oral Anticoagulant Influence in Patients Transitioning to Heparin.
    Plum MD; Hedrick JN; Hockman R; Bazydlo L; Palkimas S
    Pharmacotherapy; 2020 Sep; 40(9):880-888. PubMed ID: 32677060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients.
    Yam L; Bahjri K; Geslani V; Cotton A; Hong L
    Pharmacotherapy; 2019 Jul; 39(7):749-755. PubMed ID: 31112313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.
    Nasser MF; Jabri A; Gandhi S; Rader F
    Am J Med; 2021 Dec; 134(12):1465-1475. PubMed ID: 34403701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations.
    Levito MN; Coons JC; Verrico MM; Szymkowiak A; Legler B; Dueweke EJ; Kane-Gill SL
    Ann Pharmacother; 2021 May; 55(5):618-623. PubMed ID: 32885997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin.
    Galeano-Valle F; Pérez-Rus G; Demelo-Rodríguez P; Ordieres-Ortega L; Ortega-Morán L; Muñoz-Martín AJ; Medina-Molina S; Alvarez-Sala-Walther LA; Del-Toro-Cervera J
    Clin Transl Oncol; 2020 Aug; 22(8):1312-1320. PubMed ID: 31863355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.